Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05145907
Other study ID # TJ107001STM202
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 22, 2021
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source TJ Biopharma Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study Purpose and Design:A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 in Combination with Pembrolizumab Injection in Patients with Locally Advanced or Metastatic Solid Tumors


Description:

This open-label, multicenter phase 2 study will enroll 28 to 39 subjects in each of the following 4 cohorts Cohort 1 Triple-negative breast cancer Cohort 2 Head and neck squamous cell carcinoma Cohort 3 Other tumor species (to be determined) Cohort 4 Other tumor species (to be determined) The trial consists of two phases, the first is a safety run-in phase and the second is a case extension phase. In the safety run-in phase, 3 subjects will be treated with TJ107 (1200 µg/kg q12w) combined with Pembrolizumab Injection (200 mg q3w) first. A safety assessment was conducted by a safety assessment committee composed of the sponsor and the investigator on the first dose in these 3 subjects to determine that the dose of TJ107 1200 µg/kg was safe and to determine whether to continue the safety assessment in these 3 patients, either at this dose level, or at a dose or dosing interval adjustment (e.g., the dose of TJ107 was adjusted to 960 ug/kg or the dosing interval was adjusted). In the case expansion phase, 28-39 subjects will be enrolled in each cohort, and TJ107 (1200 µg/kg q12w) combined with Pembrolizumab Injection (200 mg q3w) or TJ107 adjusted dose combined with Pembrolizumab Injection (200 mg q3w) will be administered until intolerance or disease progression and other endpoint events occur.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 133
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female patients aged over 18 years (inclusive); - ECOG score: 0 - 2 points - Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors, including TNBC and HNSCC - No previous treatment with CPI - Agreement to provide a previously archived tumor tissue specimen or biopsy to collect tumor lesion tissue - Subject has at least 1 measurable lesion as defined by RECIST V1.1 - Expected survival = 6 months - Adequate organ function - Males of childbearing potential or females of childbearing potential must use highly effective contraceptive methods during the trial and continuing for 6 months after the last dose - The subject voluntarily joined the study and signed an informed consent form Exclusion Criteria: - Pregnant or lactating women; - Prior cell therapy; - Received systemic anti-tumor therapy within 2 weeks or 5 half-lives of the treatment agent (whichever is shorter) before the start of treatment; - Previous or current presence of two or more primary tumors - Patients with active autoimmune diseases - Have received systemic treatment with corticosteroids (10 mg prednisone equivalent daily) or other immunosuppressive agents for more than 7 days within 2 weeks before the start of treatment - Received investigational drugs within 2 weeks before the start of treatment; - Major surgery or serious trauma within 4 weeks before the start of treatment; - Patients with symptomatic central nervous system (CNS) metastasis - Active viral infectious disease requiring systemic treatment at screening: - Known serious hypersensitivity history - Uncontrolled pleural effusion, ascites, or pericardial effusion at screening; - Presence or history of active interstitial lung disease; - Patients with hypertension that cannot be well controlled with medical therapy. - Presence of clinically significant cardiovascular disease - Deep venous thrombosis within 6 months before the start of treatment - Thrombolytic therapy within 10 days prior to the start of treatment - Any active infection requiring intravenous anti-infective therapy before the start of treatment - Had toxicity not resolved to = Grade 1 (CTCAE 5.0) from previous anticancer therapy - Known or suspected inability to comply with the study protocol

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
TJ107 +Pembrolizumab
TJ107 injection:1200ug/Kg, Q12W, IM; Pembrolizumab: 200mg, Q3W, IV

Locations

Country Name City State
China Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing
China Jilin Guowen Hospital Chang chun Jilin
China Jilin Cancer Hospital Changchun Jilin
China The First Hospital of Jilin University Changchun Jilin
China The Second Xiangya Hospital of Central South University Changsha Hunan
China Hainan General Hospital Haikou Hainan
China Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang
China Zhejiang Cancer Hospital Hangzhou Zhejiang
China Harbin Medical University Cancer Hospital Harbin Heilongjiang
China The First Affiliated Hospital of Anhui Medical University Hefei Anhui
China The Second Hospital of Anhui Medical University Hefei Anhui
China Fudan University Shanghai Cancer Center Shanghai Shanghai
China Shanghai East Hospital Shanghai Shanghai
China Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine Shanghai Shanghai
China The First Hospital of China Medical University Shenyang Liaoning
China Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center Shenzhen Guangzhou
China Tianjin Medical University Cancer Institute & Hospital Tianjin Tianjin
China Hubei Cancer Hospital Wuhan Hubei
China Tongji Hospital, Tongji Medical College of Huzhong University of Science and Technology Wuhan Hubei
China Yanbian University Hospital Yanji Jilin

Sponsors (1)

Lead Sponsor Collaborator
TJ Biopharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The rate of Adverse events The rate of Adverse events Through the study assessed up to 2 years
Primary The rate of Senior Adverse Events The rate of Senior Adverse Events Through the study assessed up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT03317327 - REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors Phase 1/Phase 2
Terminated NCT02892201 - Pembrolizumab in HNSCC With Residual Disease After Radiation Phase 2
Active, not recruiting NCT04854499 - Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma Phase 2
Terminated NCT04110249 - Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer N/A
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT05338905 - Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial N/A
Recruiting NCT04045496 - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors Phase 1
Completed NCT04452214 - A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors Phase 1
Recruiting NCT04096638 - Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT03070366 - Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC Phase 2
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Terminated NCT02488629 - Study of SCB01A in Patient With Head and Neck Cancer Phase 2
Completed NCT01697800 - A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract Phase 2
Completed NCT01427478 - Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck Phase 3
Recruiting NCT05437380 - Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC N/A
Recruiting NCT05065086 - Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence
Completed NCT03022409 - A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). Phase 1